• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alignment Healthcare Reports Fourth Quarter and Full-Year 2024 Results; Provides Full-Year 2025 Financial Guidance

    2/27/25 4:01:00 PM ET
    $ALHC
    Medical Specialities
    Health Care
    Get the next $ALHC alert in real time by email
    • Reports 189,100 health plan members as of Dec. 31, 2024, up 58.6% year-over-year, beating year-end expectations
    • Achieves first full year of positive adjusted EBITDA as a public company, driven by operating leverage and strong medical benefits ratio performance
    • Raises midpoint of 2025 health plan membership guidance by 2,000 to reflect strong open enrollment period momentum
    • Introduces 2025 revenue guidance of $3.72 billion to $3.78 billion, representing 37.6%-39.6% growth year-over-year, and adjusted EBITDA of $35 million to $60 million

    ORANGE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), today reported financial results for its fourth quarter and full year ended Dec. 31, 2024.

    "2024 was a milestone year that proved health plans can win by providing more care, not less," said John Kao, founder and CEO. "By using our clinical resources and technology to improve outcomes and manage medical expenses, we grew while others pulled back. With strong momentum from the annual enrollment period and industry-leading stars performance, we enter 2025 positioned for success and confident that we are fulfilling our vision for Medicare Advantage done right."

    Fourth Quarter 2024 Financial Highlights

    All comparisons, unless otherwise noted, are to the three months ended Dec. 31, 2023.

    • Health plan membership at the end of the quarter was approximately 189,100, up 58.6% year over year
    • Total revenue was $701.2 million, up 50.7% year over year. Revenue excluding ACO REACH was $700.7 million, up 61.4% year over year
    • Adjusted gross profit was $87.9 million and loss from operations was $(22.5) million
      • Adjusted gross profit excludes depreciation and amortization of $6.8 million and selling, general, and administrative expenses of $102.1 million (which includes $14.7 million of equity-based compensation). Adjusted gross profit also excludes an additional $1.5 million of equity-based compensation recorded within medical expenses
      • Medical benefits ratio based on adjusted gross profit was 87.5%
    • Adjusted EBITDA was $1.4 million and net loss was $(31.1) million

    Full Year 2024 Financial Highlights

    All comparisons, unless otherwise noted, are to the twelve months ended Dec. 31, 2023.

    • Total revenue was $2,703.6 million, up 48.3% year over year. Revenue excluding ACO REACH was $2,702.6 million, up 59.0% year over year
    • Adjusted gross profit was $302.6 million and loss from operations was $(101.6) million
      • Adjusted gross profit excludes depreciation and amortization of $27.1 million and selling, general, and administrative expenses of $371.4 million (which includes $66.2 million of equity-based compensation). Adjusted gross profit also excludes $0.8 of restructuring costs and an additional $4.9 million of equity-based compensation recorded within medical expenses
      • Medical benefits ratio based on adjusted gross profit was 88.8%
    • Adjusted EBITDA was $1.3 million and net loss was $(128.1) million

    Adjusted Gross Profit is reconciled as follows:

     Three Months Ended December 31, Year Ended December 31,
      2024   2023   2024   2023 
    (dollars in thousands)       
    Loss from operations$(22,545) $(41,913) $(101,555) $(127,817)
    Add back:       
    Equity-based compensation (medical expenses) 1,546   1,517   4,930   7,541 
    Depreciation (medical expenses) 46   60   190   254 
    Restructuring costs (medical expenses) (1) —   —   796   — 
    Depreciation and amortization (2) 6,762   5,801   26,872   21,414 
    Selling, general, and administrative expenses 102,128   83,737   371,374   307,433 
    Total add back 110,482   91,115   404,162   336,642 
    Adjusted gross profit$87,937  $49,202  $302,607  $208,825 

    (1)  Represents severance and related costs incurred as part of a corporate restructuring, that took place during 2024, designed to streamline our organizational structure and drive operational efficiencies

    (2)  Includes $0.6 million in impairment expense related to intangible assets that were written off during the year



    Adjusted EBITDA is reconciled as follows:

     Three Months Ended December 31, Year Ended December 31,
      2024   2023   2024   2023 
    (dollars in thousands)       
    Net loss$(31,064) $(47,231) $(128,071) $(148,173)
    Less: Net loss attributable to noncontrolling interest (27)  22   36   156 
    Adjustments:           
    Interest expense 5,492   5,484   23,547   21,231 
    Depreciation and amortization (1) 6,808   5,861   27,062   21,668 
    Income tax expense (benefit) 7   (24)  21   (22)
    Equity-based compensation (2) 16,236   15,652   71,132   66,835 
    Acquisition expenses (3) —   216   26   977 
    Litigation costs (4) 892   348   2,069   2,298 
    (Gain) loss on ROU assets (5) —   —   143   (289)
    Gain on sale of property and equipment (1)  —   (9)  — 
    Restructuring costs (6) —   —   2,363   — 
    Loss on extinguishment of debt 3,020   —   3,020   — 
    Adjusted EBITDA$1,363  $(19,672) $1,339  $(35,319)

    (1)   Includes $0.6 million in impairment expense related to intangible assets that were written off during the year

    (2)   Represents equity-based compensation related to grants made in the applicable year, as well as equity-based compensation related to the timing of the IPO, which includes previously issued stock appreciation rights ("SARs") liability awards, modifications related to transaction vesting units, and grants made in conjunction with the IPO

    (3)   Represents acquisition-related fees, such as legal and advisory fees, that are non-capitalizable

    (4)   Represents certain litigation costs considered outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy

    (5)   Represents gains or losses related to ROU assets that were terminated or subleased in the respective period

    (6)   Represents severance and related costs incurred as part of a corporate restructuring, that took place during 2024, designed to streamline our organizational structure and drive operational efficiencies



    Outlook for First Quarter and Fiscal Year 2025

     Three Months Ending

    March 31, 2025
    Twelve Months Ending

    December 31, 2025
    $ MillionsLowHighLowHigh
    Health Plan Membership211,000215,000227,000233,000
    Revenue$880$895$3,720$3,775
    Adjusted Gross Profit(1)$89$97$415$445
    Adjusted EBITDA(2)$2$10$35$60

    _______________________

    1. Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as loss from operations before depreciation and amortization, clinical equity-based compensation expense, clinical restructuring costs, and selling, general, and administrative expenses. We cannot reconcile our estimated ranges for adjusted gross profit to loss from operations, the most directly comparable GAAP measure, and cannot provide estimated ranges for loss from operations, without unreasonable efforts because of the uncertainty around certain items that may impact loss from operations, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted.
    2. Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net loss before interest expense, income taxes, depreciation and amortization expense, acquisition expenses, certain litigation costs, gains or losses on right of use ("ROU") assets, gains or losses on sale of property and equipment, restructuring costs, equity-based compensation expense and loss on extinguishment of debt. We cannot reconcile our estimated ranges for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and cannot provide estimated ranges for net loss, without unreasonable efforts because of the uncertainty around certain items that may impact net loss, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted.



    Conference Call Details

    The company will host a conference call at 5 p.m. EST today to discuss these results and management's outlook for future financial and operational performance. A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/oawc6g57. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web links, and will remain available for approximately 12 months.

    About Alignment Health

    Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ:ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the first quarter ending March 31, 2025 and year ending December 31, 2025. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; the impact of shortages of qualified personnel and related increases in our labor costs. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2024, and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.



     
    Consolidated Balance Sheets

    (in thousands, except par value and share amounts)
     
     December 31,

    2024
     December 31,

    2023
    Assets   
    Current Assets:   
    Cash and cash equivalents$432,859  $202,904 
    Accounts receivable (less allowance for credit losses of $0 at December 31, 2024 and 2023) 153,904   119,749 
    Investments - current 37,791   115,914 
    Prepaid expenses and other current assets 37,084   44,970 
    Total current assets 661,638   483,537 
    Property and equipment, net 67,139   51,901 
    Right of use asset, net 7,818   9,959 
    Goodwill 34,826   34,826 
    Intangible Assets, net 4,550   5,252 
    Other assets 6,092   6,405 
    Total assets$782,063  $591,880 
    Liabilities and Stockholders' Equity   
    Current Liabilities:   
    Medical expenses payable$289,788  $205,399 
    Accounts payable and accrued expenses 22,126   23,511 
    Accrued compensation 39,931   34,112 
    Total current liabilities 351,845   263,022 
    Long-term debt, net of debt issuance costs 321,428   161,813 
    Long-term portion of lease liabilities 7,835   8,974 
    Total liabilities 681,108   433,809 
    Commitments and Contingencies   
    Stockholders' Equity:   
    Preferred stock, $.001 par value; 100,000,000 shares authorized as of December 31, 2024 and 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023 —   — 
    Common stock, $.001 par value; 1,000,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 191,778,639 and 188,951,643 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 192   189 
    Additional paid-in capital 1,107,952   1,037,015 
    Accumulated deficit (1,008,293)  (880,258)
    Total Alignment Healthcare, Inc. stockholders' equity 99,851   156,946 
    Noncontrolling interest 1,104   1,125 
    Total stockholders' equity 100,955   158,071 
      Total liabilities and stockholders' equity$782,063  $591,880 



     
    Consolidated Statements of Operations

    (in thousands, except per share amounts)
     
     Three Months Ended December 31, Year Ended December 31,
      2024   2023   2024   2023 
    Revenues:       
    Earned premiums$691,785  $459,009  $2,671,931  $1,800,933 
    Other 9,456   6,378   31,630   22,697 
    Total revenues 701,241   465,387   2,703,561   1,823,630 
    Expenses:       
    Medical expenses 614,896   417,762   2,406,870   1,622,600 
    Selling, general, and administrative expenses 102,128   83,737   371,374   307,433 
    Depreciation and amortization 6,762   5,801   26,872   21,414 
    Total expenses 723,786   507,300   2,805,116   1,951,447 
    Loss from operations (22,545)  (41,913)  (101,555)  (127,817)
    Other expenses:       
    Interest expense 5,492   5,484   23,547   21,231 
    Other (income) expenses, net —   (142)  (72)  (853)
    Loss on extinguishment of debt 3,020   —   3,020   — 
    Total other expenses 8,512   5,342   26,495   20,378 
    Loss before income taxes (31,057)  (47,255)  (128,050)  (148,195)
    Provision for income tax expense (benefit) 7   (24)  21   (22)
    Net loss$(31,064) $(47,231) $(128,071) $(148,173)
    Less: Net loss attributable to noncontrolling interest (27)  22   36   156 
    Net loss attributable to Alignment Healthcare, Inc.$(31,091) $(47,209) $(128,035) $(148,017)
    Total weighted-average common shares outstanding - basic and diluted 191,897,164   188,328,517   190,793,552   186,214,784 
    Net loss per share attributable to Alignment Healthcare, Inc. - basic and diluted$(0.16) $(0.25) $(0.67) $(0.79)



     
    Consolidated Statements of Cash Flows

    (in thousands)
     
     Year Ended December 31,
      2024   2023   2022 
    Operating Activities:     
    Net loss$(128,071) $(148,173) $(149,639)
    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:     
    Provision for credit loss 123   91   150 
    (Gain) loss on right of use assets 143   (289)  510 
    Gain on sale of property and equipment (9)  —   — 
    Depreciation and amortization 27,062   21,668   17,486 
    Amortization-debt issuance costs 1,293   1,254   1,850 
    Amortization-investment discount (2,579)  (4,917)  — 
    Amortization of payment-in-kind interest —   —   2,943 
    Loss on disposal of property and equipment —   —   101 
    Equity-based compensation 71,132   66,835   81,718 
    Non-cash lease expense 1,764   2,318   2,811 
    Loss on extinguishment of debt 3,020   —   2,196 
    Changes in operating assets and liabilities:     
    Accounts receivable (34,278)  (26,950)  (34,377)
    Prepaid expenses and other current assets 7,887   (2,863)  (14,356)
    Other assets 60   (142)  (86)
    Medical expenses payable 84,389   35,264   44,250 
    Accounts payable and accrued expenses (1,460)  (6,347)  13,743 
    Accrued compensation 5,819   6,574   3,609 
    Lease liabilities (1,525)  (3,510)  (4,214)
    Payment-in-kind interest —   —   (14,122)
       Net cash provided by (used in) operating activities 34,770   (59,187)  (45,427)
    Investing Activities:     
    Purchase of business, net of cash received —   —   (4,043)
    Purchase of investments (82,200)  (379,058)  (2,825)
    Sale of property and equipment 14   —   — 
    Maturities of investments 162,795   267,790   2,425 
    Acquisition of property and equipment (41,418)  (35,995)  (23,774)
       Net cash provided by (used in) investing activities 39,191   (147,263)  (28,217)
    Financing Activities:     
    Repurchase of noncontrolling interest —   —   (100)
    Proceeds from long-term debt 380,000   —   165,000 
    Debt issuance costs (8,792)  —   (5,196)
    Repayment of long-term debt (215,000)  —   (143,179)
    Payment of employment taxes related to release of restricted stock (350)  —   — 
    Proceeds from exercise of stock options 155   —   — 
    Contributions from noncontrolling interest holders 15   105   68 
       Net cash provided by financing activities 156,028   105   16,593 
    Net increase (decrease) in cash 229,989   (206,345)  (57,051)
    Cash, cash equivalents and restricted cash at beginning of period 204,954   411,299   468,350 
    Cash, cash equivalents and restricted cash at end of period$434,943  $204,954  $411,299 
    Supplemental disclosure of cash flow information:     
    Cash paid for interest$22,157  $19,165  $22,447 
    Supplemental non-cash investing and financing activities:     
    Acquisition of property in accounts payable$70  $59  $47 
    Purchase of business in accounts payable$—  $—  $505 
    Debt issuance costs in accounts payable$512  $—  $— 



    The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total above:

     December 31, 2024 December 31, 2023 December 31, 2022
    Cash and cash equivalents$432,859  $202,904  $409,549 
    Restricted cash in other assets 2,084   2,050   1,750 
    Total$434,943  $204,954  $411,299 



    Non-GAAP Financial Measures

    Certain of these financial measures are considered "non-GAAP" financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio, Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that our management uses to assess our operating performance. Because these measures facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

    Adjusted EBITDA

    Adjusted EBITDA is a non-GAAP financial measure that we define as net loss before interest expense, income taxes, depreciation and amortization expense, acquisition expenses, certain litigation costs, gains or losses on right of use ("ROU") assets, gains or losses on sale of property and equipment, restructuring costs, equity-based compensation expense and loss on extinguishment of debt.

    Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net loss, which is the most directly comparable financial measure calculated in accordance with GAAP.

    Our use of the term Adjusted EBITDA may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

    Medical Benefits Ratio (MBR)

    We calculate our MBR by dividing total medical expenses, excluding depreciation, equity-based compensation and clinical restructuring costs, by total revenues in a given period.

    Adjusted Gross Profit

    Adjusted gross profit is a non-GAAP financial measure that we define as loss from operations before depreciation and amortization, clinical equity-based compensation expense, clinical restructuring costs and selling, general, and administrative expenses.

    Adjusted gross profit should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted gross profit in lieu of loss from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.

    Our use of the term adjusted gross profit may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

    Investor Contact

    Harrison Zhuo

    [email protected]

    Media Contact

    Priya Shah

    mPR, Inc. for Alignment Health

    [email protected]



    Primary Logo

    Get the next $ALHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALHC

    DatePrice TargetRatingAnalyst
    12/3/2024$13.00 → $17.00Equal-Weight → Overweight
    Stephens
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    5/30/2024$10.00Outperform
    Robert W. Baird
    5/30/2024$7.75 → $11.00Neutral → Buy
    BofA Securities
    5/8/2024$6.00 → $8.00Neutral → Overweight
    Piper Sandler
    3/6/2024$4.50Underweight
    Barclays
    3/6/2024$12.00 → $6.00Overweight → Neutral
    Piper Sandler
    1/24/2024$11.00Buy
    Stifel
    More analyst ratings

    $ALHC
    SEC Filings

    See more
    • SEC Form 144 filed by Alignment Healthcare Inc.

      144 - Alignment Healthcare, Inc. (0001832466) (Subject)

      5/1/25 4:50:50 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Alignment Healthcare Inc.

      10-Q - Alignment Healthcare, Inc. (0001832466) (Filer)

      5/1/25 4:30:48 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • Alignment Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alignment Healthcare, Inc. (0001832466) (Filer)

      5/1/25 4:01:09 PM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Head James M

      3 - Alignment Healthcare, Inc. (0001832466) (Issuer)

      5/2/25 4:38:49 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • Chief Legal and Admin. Officer Joyce Christopher J sold $421,828 worth of shares (25,000 units at $16.87), decreasing direct ownership by 6% to 390,022 units (SEC Form 4)

      4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

      5/2/25 4:29:30 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • President Maroney Dawn Christine sold $4,392,195 worth of shares (230,000 units at $19.10), decreasing direct ownership by 10% to 2,132,899 units (SEC Form 4)

      4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

      4/16/25 5:04:00 PM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alignment Healthcare Inc.

      SC 13G/A - Alignment Healthcare, Inc. (0001832466) (Subject)

      11/14/24 5:57:27 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alignment Healthcare Inc.

      SC 13G/A - Alignment Healthcare, Inc. (0001832466) (Subject)

      11/14/24 1:28:35 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alignment Healthcare Inc.

      SC 13G/A - Alignment Healthcare, Inc. (0001832466) (Subject)

      11/12/24 1:26:14 PM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alignment Healthcare upgraded by Stephens with a new price target

      Stephens upgraded Alignment Healthcare from Equal-Weight to Overweight and set a new price target of $17.00 from $13.00 previously

      12/3/24 7:13:50 AM ET
      $ALHC
      Medical Specialities
      Health Care
    • KeyBanc Capital Markets initiated coverage on Alignment Healthcare

      KeyBanc Capital Markets initiated coverage of Alignment Healthcare with a rating of Sector Weight

      10/11/24 7:29:52 AM ET
      $ALHC
      Medical Specialities
      Health Care
    • Robert W. Baird initiated coverage on Alignment Healthcare with a new price target

      Robert W. Baird initiated coverage of Alignment Healthcare with a rating of Outperform and set a new price target of $10.00

      5/30/24 7:29:29 AM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kao John E bought $496,779 worth of shares (103,000 units at $4.82), increasing direct ownership by 4% to 2,745,253 units (SEC Form 4)

      4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

      3/18/24 5:27:36 PM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition

      Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 membersExceeds high-end of Q1 guidance on membership, revenue, adjusted gross profit and adjusted EBITDARaises midpoint of outlook ranges for 2025 year-end membership, revenue, adjusted gross profit and adjusted EBITDA, supported by strong first-quarter clinical performance and enrollment growth momentumAnnounces transition of Thomas Freeman from Chief Financial Officer (CFO) to Strategic Advisor to the CEO; names finance veteran Jim Head as CFO ORANGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), today reporte

      5/1/25 4:01:00 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • Alignment Healthcare to Present at the BofA Securities Healthcare Conference

      ORANGE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), today announced that it will present at the BofA Securities Healthcare Conference on Wednesday, May 14, at 2:20 p.m. PDT. A webcast and replay of the presentations will be available on Alignment's investor relations website at https://ir.alignmenthealth.com/. About Alignment HealthcareAlignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ:ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day.

      4/28/25 8:00:00 AM ET
      $ALHC
      Medical Specialities
      Health Care
    • Alignment Healthcare Strengthens Leadership to Scale its AI-Enabled Medicare Advantage Platform with Two Key Appointments

      ORANGE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC) today announced pivotal leadership appointments that underscore its dedication to transforming senior health care through technology and exceptional member care. Dr. Arta Bakshandeh has been named President of AVA®, and Aly Duzich has been promoted to Chief Experience Officer. Driving Next-Generation InnovationFor more than 10 years, Alignment has harnessed trusted artificial intelligence (AI) through AVA – the company's proprietary Medicare Advantage platform – to drive actionable clinical insights that improve senior health outcomes and quality of care. Dr. Bakshandeh's appointment reinforces Ali

      4/15/25 8:00:00 AM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Financials

    Live finance-specific insights

    See more
    • Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition

      Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 membersExceeds high-end of Q1 guidance on membership, revenue, adjusted gross profit and adjusted EBITDARaises midpoint of outlook ranges for 2025 year-end membership, revenue, adjusted gross profit and adjusted EBITDA, supported by strong first-quarter clinical performance and enrollment growth momentumAnnounces transition of Thomas Freeman from Chief Financial Officer (CFO) to Strategic Advisor to the CEO; names finance veteran Jim Head as CFO ORANGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), today reporte

      5/1/25 4:01:00 PM ET
      $ALHC
      Medical Specialities
      Health Care
    • Alignment Healthcare to Announce First Quarter 2025 Financial Results and Host Conference Call Thursday, May 1, 2025

      ORANGE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), will release its first quarter 2025 financial results on Thursday, May 1, 2025, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EDT. Conference Call DetailsA live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/frtkwokr A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same web links and will

      4/11/25 8:00:00 AM ET
      $ALHC
      Medical Specialities
      Health Care
    • Alignment Healthcare Reports Fourth Quarter and Full-Year 2024 Results; Provides Full-Year 2025 Financial Guidance

      Reports 189,100 health plan members as of Dec. 31, 2024, up 58.6% year-over-year, beating year-end expectationsAchieves first full year of positive adjusted EBITDA as a public company, driven by operating leverage and strong medical benefits ratio performanceRaises midpoint of 2025 health plan membership guidance by 2,000 to reflect strong open enrollment period momentumIntroduces 2025 revenue guidance of $3.72 billion to $3.78 billion, representing 37.6%-39.6% growth year-over-year, and adjusted EBITDA of $35 million to $60 million ORANGE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC), today reported financial results for its fourth quarter and full y

      2/27/25 4:01:00 PM ET
      $ALHC
      Medical Specialities
      Health Care

    $ALHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Alignment Healthcare Appoints Sebastian Burzacchi to New Role of Chief Operating Officer of Management Services Organization and Andreas Wagner to Chief People Officer

      ORANGE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC) today announced that Sebastian Burzacchi will join as the new chief operating officer of its management services organization (MSO), and Andreas Wagner will serve as chief people officer, effective immediately. Sebastian Burzacchi, Chief Operating Officer of MSOReporting to Alignment founder and CEO John Kao, Sebastian Burzacchi will direct initiatives that strengthen a core value of the company – supporting doctors. This includes a focus on enhancing provider partnerships and ensuring a seamless experience for doctors with Alignment. "We are thrilled to welcome Sebastian to our leadership team, br

      1/9/24 8:00:00 AM ET
      $ALHC
      Medical Specialities
      Health Care
    • Alignment Health Welcomes New Chief People Officer as It Scales to Serve More Seniors Nationwide

      ORANGE, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Alignment Health — a consumer brand name of Alignment Healthcare, Inc. (NASDAQ:ALHC), a tech-enabled Medicare Advantage company — today announced the appointment of Melinda Kimbro as its new chief people officer. Kimbro joined on June 30 to lead the company's human resources (HR) function and will oversee all aspects of the Alignment employee experience, including talent acquisition, culture, diversity, equity and inclusion, total rewards, and facilities. She will also spearhead the strategic development of internal talent to help further drive innovation and provide rich, ongoing career growth opportunities for employees. "Championing ou

      7/6/23 8:00:00 AM ET
      $ALHC
      $VSAT
      Medical Specialities
      Health Care
      Radio And Television Broadcasting And Communications Equipment
      Technology
    • Alignment Health Appoints 3 New Executives to Further Drive Strategic Growth Nationally

      ORANGE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alignment Health, a consumer brand name of Alignment Healthcare, Inc. (NASDAQ:ALHC), a tech-enabled Medicare Advantage (MA) company, is strengthening its sales team with the addition of three executives who will help propel the company's nationwide growth as it champions a new path in senior care. Appointed as Health Plan Chief Growth Officer, Todd Macaluso will lead the company's health plan growth by increasing net membership and improving the overall experience, execution, research and development efforts. David Milligan and Joe Kanatzar will serve as senior vice presidents of sales for California and all states outside California, resp

      6/6/23 8:00:00 AM ET
      $ALHC
      Medical Specialities
      Health Care